4-amino-N-(2-dimethylaminoethyl)-benzenesulfonamide | 77837-46-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-amino-N-(2-dimethylaminoethyl)-benzenesulfonamide
• 英文别名: N,N-dimethyl-N'-(4-aminophenylsulfonyl)-ethylenediamine；4-amino-N-(2-dimethylaminoethyl)benzenesulfonamide；sulfanilic acid-(2-dimethylamino-ethylamide)；N'-Sulfanilyl-N.N-dimethyl-aethylendiamin；Sulfanilsaeure-(2-dimethylamino-aethylamid)；4-amino-N-(2-(dimethylamino)ethyl)benzenesulfonamide；4-amino-N-[2-(dimethylamino)ethyl]benzene-1-sulfonamide；4-amino-N-[2-(dimethylamino)ethyl]benzenesulfonamide
• CAS: 77837-46-8
• 化学式: C₁₀H₁₇N₃O₂S
• mdl: MFCD01683089
• 分子量: 243.33
• InChiKey: HERALKCUSVEQOM-UHFFFAOYSA-N

物化性质

• 熔点：
  80-82 °C(Solv: water (7732-18-5))
• 沸点：
  402.2±55.0 °C(Predicted)
• 密度：
  1.222±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-amino-N-(2-dimethylaminoethyl)-benzenesulfonamide 在 肼 作用下， 以 四氢呋喃 为溶剂， 生成 4-(5-Amino-1H-[1,2,4]triazol-3-ylamino)-N-(2-dimethylamino-ethyl)-benzenesulfonamide
  参考文献：
  名称：

  1-Acyl-1H-[1,2,4]triazole-3,5-diamine Analogues as Novel and Potent Anticancer Cyclin-Dependent Kinase Inhibitors:  Synthesis and Evaluation of Biological Activities

  摘要：

  A series of 1-acyl-1H-[1,2,4]triazole-3,5-diamine analogues were synthesized as cyclin-dependent kinase (CDK) inhibitors. These compounds showed potent and selective CDK1 and CDK2 inhibitory activities and inhibited in vitro cellular proliferation in various human tumor cells. Representative compound 3b demonstrated in vivo efficacy in a human melanoma A375 xenograft model in nude mice.

  DOI：

  10.1021/jm050267e
• 作为产物：
  描述：

  N,N-dimethyl-N'-(4-nitrophenylsulfonyl)-ethylenediamine 在 palladium on activated charcoal 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、300.0 kPa 条件下， 反应 3.0h， 以100%的产率得到4-amino-N-(2-dimethylaminoethyl)-benzenesulfonamide
  参考文献：
  名称：

  Artificial Transfer Hydrogenases Based on the Biotin−(Strept)avidin Technology:  Fine Tuning the Selectivity by Saturation Mutagenesis of the Host Protein

  摘要：

  Incorporation of biotinylated racemic three-legged d(6)-piano stool complexes in streptavidin yields enantioselective transfer hydrogenation artificial metalloenzymes for the reduction of ketones. Having identified the most promising organometallic catalyst precursors in the presence of wild-type streptavidin, fine-tuning of the selectivity is achieved by saturation mutagenesis at position S112. This choice for the genetic optimization site is suggested by docking studies which reveal that this position lies closest to the biotinylated metal upon incorporation into streptavidin. For aromatic ketones, the reaction proceeds smoothly to afford the corresponding enantioenriched alcohols in up to 97% ee (R) or 70% (S). On the basis of these results, we suggest that the enantioselection is mostly dictated by CH/pi interactions between the substrate and the eta(6)-bound arene. However, these enantiodiscriminating interactions can be outweighed in the presence of cationic residues at position S112 to afford the opposite enantiomers of the product.

  DOI：

  10.1021/ja061580o

文献信息

• SUBSTITUTED CINNAMIC, ACID GUANIDIDES, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, AND MEDICAMENT COMPRISING THEM
  申请人：Aventis Pharma Deutschland GmbH.

  公开号：US20020058710A1

  公开（公告）日：2002-05-16

  Substituted cinnamic acid guanidides, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the 1 , which may be obtained by reaction of a compound II 2 with guanidine.

  苯丙烯酸胍衍生物，其制备方法，作为药物或诊断用途的使用，以及包含它们的药物。可以通过化合物II2与胍反应获得的化合物1。
• Thiazolidinones, their production and use as pharmaceutical agents
  申请人：Siemeister Gerhard

  公开号：US20070037862A1

  公开（公告）日：2007-02-15

  Thiazolidinones of general formula I in which Q, A, B, X, R 1 and R 2 have the meanings that are indicated in the description, as well as those of general formula IA in which Q, A, B, X, R 1 and R 2a have the meanings that are indicated in the description, their production and use as inhibitors of the polo-like kinase (PLK) for treating various diseases as well as intermediate products for the production of thiazolidinones are described.

  通用公式I中的噻唑烷酮，其中Q、A、B、X、R1和R2具有描述中指示的含义，以及通用公式IA中的噻唑烷酮，其中Q、A、B、X、R1和R2ahave具有描述中指示的含义，描述了它们作为极化样激酶（PLK）抑制剂用于治疗各种疾病以及用于噻唑烷酮的生产和使用的中间体产品。
• Pyrrolo[2,3-d]pyrimidine compounds
  申请人：——

  公开号：US20020068746A1

  公开（公告）日：2002-06-06

  A compound of the formula 1 wherein R 1 , R 2 and R 3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

  一种具有上述定义的R1、R2和R3的化合物，用作蛋白激酶抑制剂，例如酶Janus激酶3。
• Pyrrolo[2,3-D]pyrimidine compounds
  申请人：Blumenkopf A. Todd

  公开号：US20050197349A1

  公开（公告）日：2005-09-08

  A compound of the formula wherein R 1 , R 2 and R 3 are as defined above, useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3.

  一种化合物的公式，其中R1，R2和R3如上所定义，可用作蛋白激酶的抑制剂，例如酶Janus Kinase 3。
• Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
  申请人：Kley Joerg

  公开号：US20050054710A1

  公开（公告）日：2005-03-10

  The present invention relates to heterocyclically substituted indolinones of general formula wherein R 1 to R 5 and X are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, in particular an inhibiting effect on various receptor tyrosine kinases and cyclin/CDK complexes and on the proliferation of endothelial cells and various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式为的杂环取代吲哚酮 其中R1至R5和X的定义如权利要求1中所述，其互变异构体、对映异构体、混合物、前药及其盐，特别是具有有价值的药理学特性，特别是对各种受体酪氨酸激酶和环/ CDK复合物以及内皮细胞和各种肿瘤细胞的增殖具有抑制作用的生理上可接受的盐，包含这些化合物的制药组合物，它们的用途和制备它们的过程。